Hill-Rom Reports Strong Fiscal Third Quarter 2018 Financial Results

CHICAGO, July 27, 2018 /PRNewswire/ -- Hill-Rom Holdings, Inc. (NYSE: HRC), today announced financial results for its fiscal third quarter ended June 30, 2018, and reaffirmed its fiscal 2018 full-year outlook.

For the fiscal third quarter, Hill-Rom reported earnings of $0.67 per diluted share compared to $0.09 per diluted share in the prior-year period. On an adjusted basis, excluding special items, earnings of $1.15 per diluted share rose 26 percent from $0.91 per diluted share in the prior-year period, exceeding the company's previously-issued guidance of $1.12 to $1.14 per diluted share. Adjustments to reported earnings are detailed in the reconciliation schedules provided. 

"Since joining Hill-Rom in May, I have immersed myself in the business, thoroughly reviewing the company and its global operations and engaging with our employees, business leaders, customers and partners," said John P. Groetelaars, Hill-Rom's president and chief executive officer. "It's clear to me that Hill-Rom has a solid foundation and compelling growth prospects, as reflected in our strong fiscal third quarter financial results. I am confident in Hill-Rom's future as we enter the next phase of our transformation with the momentum to drive growth through innovation and business development initiatives, and create long-term value for patients, customers and shareholders."

Fiscal Third Quarter Financial Results

In the fiscal third quarter, Hill-Rom's worldwide revenue of $709 million increased 3 percent compared to the fiscal third quarter of last year, or 1 percent on a constant currency basis. Domestic revenue of $494 million advanced 5 percent, while revenue outside the U.S. of $215 million declined 2 percent, or 7 percent on a constant currency basis.  

Hill-Rom's core revenue accelerated by 4 percent on a constant currency basis, as the company capitalized on several new product introductions from across the portfolio. Core revenue excludes foreign currency, divestitures and non-strategic assets the company plans to exit.

By reporting segment:

• Patient Support Systems: Patient Support Systems revenue of $360 million increased 1 percent on a reported basis, and was comparable to the prior-year period on a constant currency basis. Core revenue accelerated by 5 percent, primarily the result of significant growth in key U.S. product categories, including Med-Surg bed systems, Clinical Workflow Solutions and patient handling equipment, of more than 20 percent.
  
  
• Front Line Care: Front Line Care, which includes Welch Allyn, Respiratory Care and Mortara, generated revenue of $239 million, an increase of 5 percent on a reported basis, and 4 percent on a constant currency basis, driven by contributions from new products.
  
  
• Surgical Solutions: Surgical Solutions revenue of $110 million increased 2 percent on a reported basis, and was comparable to the prior-year period on a constant currency basis, reflecting a challenging international comparison to last year.

Gross margin of 49.1 percent expanded 110 basis points compared to the prior year, and operating margin improved 520 basis points to 11.1 percent. On an adjusted basis, gross margin expanded by 80 basis points to 49.1 percent and operating margin improved by 120 basis points to 17.3 percent. Adjustments to gross margin and operating margin are detailed in the reconciliation schedules provided.

Year-to-date, operating cash flow of $250 million increased 4 percent versus the prior-year period, and the company returned $46 million to shareholders in the form of dividends and share repurchases.

Recent Highlights 

Complementing the company's financial performance were several recent achievements aimed at delivering sustainable value through innovation and strategic investments. Highlights include:

• Enhancing commercial execution and achieving more than $180 million in new product revenue through the first nine months of fiscal 2018. Contributing to this performance are several innovative products, such as:
  
  
• Centrella™ Smart+ bed, which transforms care by providing optimized patient safety, enhanced patient satisfaction and advanced caregiver efficiency. Now available in the U.S. and Canada, the new scalable platform integrates with the NaviCare® Patient Safety application, including integrated technology, services, clinical programs and clinical expertise to prevent and reduce the risk of falls. The company expects to launch Centrella in various international markets in the coming months.
  
  
• Integrated Table Motion for the da Vinci® Xi® Surgical System, which allows surgeons and anesthesiologists – for the first time – to make a comprehensive range of table adjustments easily and efficiently during surgery.
  
  
• Welch Allyn Connex® Spot Monitor, an easy-to-use, full-color, touchscreen monitor that provides comprehensive and accurate patient vital signs (blood pressure measurement, pulse oximetry for assessing respiratory conditions, and thermometry) documentation using a single device.
  
  
• Welch Allyn's vision care portfolio including the Spot™ Vision Screener, a handheld, portable device allowing clinicians to quickly detect vision issues; and the Welch Allyn® RetinaVue™ 100 Imager, a breakthrough handheld technology which makes diabetic retinopathy screening simple and affordable for primary care settings.
  
  
• Monarch™ Airway Clearance System, which builds high frequency chest wall oscillation therapy into a mobile vest, allowing a patient to be active and productive while receiving therapy.
  
  
• Advancing the company's leadership in patient support systems with continued investment and expansion of the company's clinical workflow solutions and communication platforms. This includes the recent limited release of Linq™ mobile, a smartphone application that securely connects members of the care team to each other, to their patients, and to patient information in real-time. With the full commercial launch planned later this year, the Linq mobile platform integrates clinical workflows with nurse call, clinical surveillance and monitoring systems, improving care-team collaboration, communication and efficiency. Hill-Rom continues to invest in technology that accesses critical information in the patient-care environment to provide caregivers with actionable insights that improve care and enhance patient outcomes. 
  
  
• Driving innovation with the launch of a new magnetic resonance neurosurgical table for the IMRIS Surgical Theatre. Developed in collaboration with clinicians, designers and engineers, the new table integrates a novel IMRIS magnetic resonance neurosurgical tabletop with Hill-Rom's TruSystem™ 7500 OR Table platform, maximizing utilization and improving ergonomic and multi-functional capabilities.

Fiscal Fourth Quarter and Full-Year 2018 Financial Outlook

Hill-Rom provided its fiscal fourth quarter financial outlook and reaffirmed its full-year guidance. For the fiscal fourth quarter 2018, Hill-Rom expects revenue to increase approximately 2 percent on both a reported and constant currency basis, and core revenue to increase 3 to 4 percent. Hill-Rom expects adjusted earnings, excluding special items, of $1.50 to $1.53 per diluted share.

For full-year 2018, Hill-Rom continues to expect revenue to increase 3 to 4 percent on a reported basis and 2 to 3 percent on a constant currency basis. The company continues to expect core revenue to increase approximately 3 percent. Core revenue excludes foreign currency, divestitures, non-strategic assets the company plans to exit, and Mortara revenue prior to the anniversary date of the acquisition. Hill-Rom now expects adjusted earnings, excluding special items, of $4.62 to $4.65 per diluted share, compared to its prior guidance of $4.60 to $4.65 per diluted share, and approximately $350 million in operating cash flow. 

Discussion of Adjusted Financial Measures

In addition to the results reported in accordance with GAAP, Hill-Rom routinely provides gross margin, operating margin, income tax expense, and earnings per diluted share results on an adjusted basis because the company's management believes these measures contribute to an understanding of our financial performance and provide additional analytical tools to understand our results from core operations and reveal underlying operating trends. These measures exclude strategic developments, acquisition and integration costs, special charges, the one-time impact of the new U.S. tax reform legislation, and other unusual events. The company also excludes expenses associated with the amortization of intangible assets associated with prior business acquisitions. These adjustments are made to allow investors to evaluate and understand operating trends excluding the non-cash impact of acquired intangible amortization on operating income and earnings per diluted share.

Management uses these measures internally for planning, forecasting and evaluating the performance of the business. Investors should consider these non-GAAP measures in addition to, not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Reconciliations of GAAP measures to adjusted measures appear in the financial tables of this release.

The company also routinely provides earnings per diluted share guidance on an adjusted basis. This excludes the impact of intangible asset amortization associated with prior business acquisitions, which we expect to be $1.15 to $1.20 per diluted share for the fiscal year, and the one-time impact of new U.S. tax reform legislation we expect to record during fiscal 2018. Management also does not include adjusted items such as strategic developments, acquisition and integration costs, special charges, and other unusual items in our guidance because such items are evaluated on an ongoing basis, can be highly variable and cannot be reasonably predicted. As such, prospective quantification of these items is not feasible and a full reconciliation of non-GAAP earnings per diluted share guidance to GAAP earnings per diluted share has not been provided. However, as a result of significant recent acquisitions, our ongoing footprint and portfolio optimization, and the new U.S. tax reform legislation, we do expect adjusted items we have not predicted to potentially be significant to our GAAP measures including gross margin, operating margin, income tax expense and earnings per diluted share.

The company also presents certain results on a constant currency basis, which compares results between periods as if foreign currency exchange rates had remained consistent period-over-period. Management monitors sales performance on an adjusted basis that eliminates the positive or negative effects that result from translating international sales into U.S. dollars. Management calculates constant currency by applying the foreign currency exchange rate for the prior period to the local currency results for the current period.

Conference Call Webcast and Dial-in Information

The company will host a conference call and webcast today beginning at 7:00 a.m. (CT) / 8:00 a.m. (ET).

Conference Call Audio Only Dial-in Information: To participate in the conference call, dial (844) 654-5620 (domestic) or (647) 253-8654 (international). Please dial into the call at least 10 minutes prior to the start to allow time to connect. The confirmation code is 8837608.

Webcast: A simultaneous webcast of the call will be accessible via the company's website at www.hill-rom.com.

Presentation: A supplementary presentation will be posted to the Hill-Rom website prior to the webcast.

A recording of the webcast/call audio will be available for telephone replay through August 3, 2018. To access the replay, dial (800) 585-8367 (domestic) or (416) 621-4642 (international). For the replay, callers will need to use confirmation code 8837608. If you are unable to listen to the live webcast or the telephone replay, the webcast will be archived at www.hill-rom.com.

About Hill-Rom Holdings, Inc.

Hill-Rom is a leading global medical technology company with more than 10,000 employees worldwide. We partner with health care providers in more than 100 countries, across all care settings, by focusing on patient care solutions that improve clinical and economic outcomes in five core areas: Advancing Mobility, Wound Care and Prevention, Patient Monitoring and Diagnostics, Surgical Safety and Efficiency and Respiratory Health. Our innovations ensure caregivers have the products they need to help diagnose, treat and protect their patients; speed up recoveries; and manage conditions. Every day, around the world, we enhance outcomes for patients and their caregivers. Learn more at hill-rom.com.

Disclosure Regarding Forward-Looking Statements 

Certain statements herein contain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, regarding the company's future plans, proposed divestitures, product launches, objectives, beliefs, expectations, representations and projections. It is important to note that forward-looking statements are not guarantees of future performance, and the company's actual results could differ materially from those set forth in any forward-looking statements. For a more in-depth discussion of factors that could cause actual results to differ from those contained in forward-looking statements, see the discussions under the heading "Risk Factors" in the company's previously filed most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The company assumes no obligation to update or revise any forward-looking statements, unless required by law.  

SOURCE Hill-Rom Holdings, Inc.

Related Links

http://www.hill-rom.com